DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4
DURECT Corporation (Nasdaq: DRRX) will report its financial results for Q2 2022 on August 4, 2022, at 4:30 PM ET. The call will also provide a business update, wherein the company is focused on advancing therapies for acute organ injury and chronic liver diseases, particularly with its lead drug candidate, larsucosterol (DUR-928), for alcohol-associated hepatitis (AH), with FDA Fast Track Designation. The drug is also being explored for non-alcoholic steatohepatitis (NASH).
- Larsucosterol (DUR-928) received FDA Fast Track Designation for alcohol-associated hepatitis.
- DURECT is advancing potentially lifesaving therapies for acute organ injury and chronic liver diseases.
- Risks include potential delays in clinical trials due to COVID-19.
- Ongoing trials may not confirm earlier results regarding safety and efficacy.
CUPERTINO, Calif., July 27, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022.
Thursday, August 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time | |
Toll Free: | 1-877-869-3847 |
International: | 201-689-8261 |
Conference ID: | 13731890 |
Webcast: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=oxQ1dFOB |
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement.
The statements in this press release regarding clinical development of larsucosterol (DUR-928) for potential treatment of AH, the potential to develop larsucosterol for NASH or other indications, the expected commercial launch of POSIMIR by Innocoll and potential future payments we may receive from Innocoll are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the AHFIRM trial of larsucosterol in AH takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that ongoing and future clinical trials of larsucosterol do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life-saving potential of larsucosterol in a statistically significant manner, risks that Innocoll may not commercialize POSIMIR successfully, if at all, and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's quarterly report on Form 10-Q filed on May 5, 2022 with the Securities and Exchange Commission under the heading "Risk Factors." The 10-Q and other public filings are available on our website www.durect.com under the "Investors" tab.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
View original content:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-second-quarter-2022-financial-results-and-provide-business-update-on-august-4-301594731.html
SOURCE DURECT Corporation
FAQ
When will DURECT Corporation announce its Q2 2022 financial results?
What is larsucosterol (DUR-928) being developed for?
What is the significance of FDA Fast Track Designation for DURECT?
What are the risks associated with DURECT's clinical trials?
How can I attend DURECT's Q2 2022 conference call?
